Royal UNIBREW A/S (0R6Z)
London Exchange · UK · prices in DKK · close of 22 Oct 2026
Key indicators
| Last close | DKK 443.20 |
|---|---|
| 52-week range | 394.20 – 652.50 |
| Return, 1 month / 3 months | +4.8% / −8.7% |
| Return, 1 year / 3 years | −9.2% / −5.2% |
| Trend | Below its 200-day average |
| RSI (14) | 68 |
| Volatility (1 year) | 37.6% |
| Worst drawdown (1 year) | -39.3% |
| Average daily value traded | 7.39M DKK |
| Dividend yield | 3.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Royal Unibrew is a Danish beverage company based in Faxe that brews beer and makes soft drinks, cider, malt beverages and bottled water. Its brands include Faxe, Ceres, Royal and Albani, and it serves consumers through retailers, restaurants and other outlets. The company operates breweries and production sites in Denmark and other European countries, with its main markets in the Nordic region and the Baltic states. It also produces and distributes beverages for partners alongside its own labels.
Royal UNIBREW A/S trades under the code 0R6Z on the London Exchange in UK, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Royal UNIBREW A/S (0R6Z) trades on the London Exchange in UK. It last closed at DKK 443.20 on 22 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 2,460 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 9.2% and over the last three months it fell 8.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.2% | ||
| From 52-week high | -32.0% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.7% | ||
| 6-month return | 16.4% | ||
| 12-month return, skipping the last month | -13.3% | ||
| Stability (higher is calmer) | 39 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 37.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.3% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 7.39M DKK | ||
| Zero-volume days | 8.3% | ||
| Income | 51 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.6% |
|---|---|
| 1 month | +4.8% |
| 3 months | −8.7% |
| 6 months | +16.4% |
| 1 year | −9.2% |
| 3 years | −5.2% |
| 5 years | −35.2% |
Signals
| 50-day / 200-day average | 423.77 / 477.56 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 10.91 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Apr 2026 | DKK 16.0000 |
| 30 Apr 2025 | DKK 15.0000 |
| 1 Oct 2024 | DKK 14.5000 |
| 28 Apr 2023 | DKK 14.5000 |
| 29 Apr 2022 | DKK 14.5000 |
| 29 Apr 2021 | DKK 13.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.